ABXL Market Analysis
News & Sentiment
47 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- 9.5%
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About ABXL
Company profileAbraxas BioScience (ABXL) is a pioneering biopharmaceutical firm committed to addressing critical medical needs through the development of innovative therapies. With a focus on leveraging cutting-edge technologies in drug discovery, ABXL boasts a promising pipeline of proprietary drug candidates aimed at enhancing patient outcomes in areas of high unmet medical need. The company emphasizes scientific excellence and adheres to rigorous regulatory standards, fostering collaborations with leading academic institutions and industry stakeholders to accelerate the advancement of transformative…
Company profile
- HQ
- NONE
- Latest quarter
- —
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer